PT  - JOURNAL ARTICLE
AU  - JEAN-DAVID FUMET
AU  - JULIE VINCENT
AU  - LEILA BENGRINE
AU  - AUDREY HENNEQUIN
AU  - LAURA GRANCONATO
AU  - REMI PALMIER
AU  - FRANÇOIS GHIRINGHELLI
TI  - Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
AID  - 10.21873/anticanres.14395
DP  - 2020 Jul 01
TA  - Anticancer Research
PG  - 4011--4015
VI  - 40
IP  - 7
4099  - http://ar.iiarjournals.org/content/40/7/4011.short
4100  - http://ar.iiarjournals.org/content/40/7/4011.full
SO  - Anticancer Res2020 Jul 01; 40
AB  - Background/Aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX. Patients and Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Results: During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months. Conclusion: Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes.